Cancer Discovery

Read the current issue of Cancer Discovery.

Research Assistant (m/f/x) Full Time [Ref 2309]

Our Institute, Our GroupThe Research Institute of Molecular Pathology (IMP) in Vienna pursues world-class research in basic molecular biology. It is located at the Vienna BioCenter and largely sponsor

Fondazione Pezcoller on Twitter

“Excited to share the program of 2023 Pezcoller Symposium, with a tremendous lineup of speakers! Mark it on your calendar: 💡 NEW TECHNOLOGIES FOR STUDYING AND TREATING CANCER 🗓️ June 19-20, Trento Here more info: https://t.co/OBkYH3ga7A #Pezcoller23 #cancerresearch #networking”

Introduction | 3rd EACR Early Career Researchers' Conference | The European Association for Cancer Research

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating

AbstractThe success of chimeric antigen receptor (CAR) T cells targeting B-cell malignancies propelled the field of synthetic immunology and raised hopes to treat solid tumors in a similar fashion. Antigen escape and the paucity of tumor-restricted CAR targets are recognized challenges to fulfilling this prospect. Recent advances in CAR T cell engineering extend the toolbox of chimeric receptors available to calibrate antigen sensitivity and combine receptors to create adapted tumor-sensing T cells. Emerging engineering strategies to lower the threshold for effective antigen recognition, when needed, and enable composite antigen recognition hold great promise for overcoming tumor heterogeneity and curbing off-tumor toxicities.Significance:. Improving the clinical efficacy of CAR T cell therapies will require engineering T cells that overcome heterogeneous and low-abundance target expression while minimizing reactivity to normal tissues. Recent advances in CAR design and logic gating are poised to extend the success of CAR T cell therapies beyond B-cell malignancies.